Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „additional“
Suchtreffer
Begriffe & Kennungen
CoAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenCoAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenCoAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenCoAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenCoAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenCoAprovel · 4.8 · Additional information on individual components: in addition to the adverse reactions listed above for the com
Eintrag öffnenCoAprovel · 4.8 · Additional information on individual components: in addition to the adverse reactions listed above for the com
Eintrag öffnenCoAprovel · 4.8 · Additional information on individual components: in addition to the adverse reactions listed above for the com
Eintrag öffnenCoAprovel · 4.8 · Additional information on individual components: in addition to the adverse reactions listed above for the com
Eintrag öffnenCoAprovel · 4.8 · Additional information on individual components: in addition to the adverse reactions listed above for the com
Eintrag öffnenCopalia · 4.8 · 11 Additional information on the combination
Eintrag öffnenCopalia · 4.8 · Additional information on the individual components
Eintrag öffnenDafiro · 4.8 · 11 Additional information on the combination
Eintrag öffnenDafiro · 4.8 · Additional information on the individual components
Eintrag öffnenDarunavir Krka · 4.5 · Alternative or additional ethinylestradiol AUC ↓ 44% β contraceptive measures are Ethinylestradiol ethinylestr
Eintrag öffnenDegevma · 4.8 · Study 7 was conducted to continue to follow subjects with GCTB who were treated in study 6 for an additional 5
Eintrag öffnenDuavive · 4.8 · 10 Incidence per 1,000 Additional cases per Age at start never-users of HRT over Risk ratio 1,000 HRT users af
Eintrag öffnenDuavive · 4.8 · Estimated additional risk of breast cancer after 10 years’ use in women with BMI 27 (kg/m 2)
Eintrag öffnenDuavive · 4.8 · Estimated additional risk of breast cancer after 5 years’ use in women with BMI 27 (kg/m 2) Incidence per 1,00
Eintrag öffnenDuavive · 4.8 · US WHI Oestrogen only (ET) arm – additional risk of breast cancer after 5 years’ use Incidence per 1,000 Addit
Eintrag öffnen